首页> 外文期刊>Anesthesiology >A randomized, double-masked, multicenter comparison of the safety of continuous intrathecal labor analgesia using a 28-gauge catheter versus continuous epidural labor analgesia.
【24h】

A randomized, double-masked, multicenter comparison of the safety of continuous intrathecal labor analgesia using a 28-gauge catheter versus continuous epidural labor analgesia.

机译:使用28号导管与连续硬膜外分娩镇痛的连续鞘内分娩镇痛的安全性的随机,双掩盖,多中心比较。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Continuous intrathecal labor analgesia produces rapid analgesia or anesthesia and allows substantial flexibility in medication choice. The US Food and Drug Administration, in 1992, removed intrathecal microcatheters (27-32 gauge) from clinical use after reports of neurologic injury in nonobstetric patients. This study examined the safety and efficacy of a 28-gauge intrathecal catheter for labor analgesia in a prospective, randomized, multicenter trial. METHODS: Laboring patients were randomly assigned to continuous intrathecal analgesia with a 28-gauge catheter (n = 329) or continuous epidural analgesia with a 20-gauge catheter (n = 100), using bupivacaine and sufentanil. The primary outcome was the incidence of neurologic complications, as determined by masked neurologic examinations at 24 and 48 h postpartum, plus telephone follow-up at 7-10 and 30 days after delivery. The secondary outcomes included adequacy of labor analgesia, maternal satisfaction, and neonatal status. RESULTS: No patient had a permanent neurologic change. The continuous intrathecal analgesia patients had better early analgesia, less motor blockade, more pruritus, and higher maternal satisfaction with pain relief at 24 h postpartum. The intrathecal catheter was significantly more difficult to remove. There were no significant differences between the two groups in neonatal status, post-dural puncture headache, hemodynamic stability, or obstetric outcomes. CONCLUSIONS: Providing intrathecal labor analgesia with sufentanil and bupivacaine via a 28-gauge catheter has an incidence of neurologic complication less than 1%, and produces better initial pain relief and higher maternal satisfaction, but is associated with more technical difficulties and catheter failures compared with epidural analgesia.
机译:背景:持续的鞘内分娩镇痛可产生快速的镇痛或麻醉作用,并在药物选择上具有很大的灵活性。有报道称非产科患者发生神经损伤后,美国食品药品监督管理局于1992年从临床使用中删除了鞘内微导管(27-32号)。这项研究在一项前瞻性,随机,多中心试验中检查了28号鞘内导管对分娩镇痛的安全性和有效性。方法:使用布比卡因和舒芬太尼,将分娩的患者随机分配使用28号导管(n = 329)进行鞘内连续镇痛或使用20号导管(n = 100)进行硬膜外连续镇痛。主要结果是神经系统并发症的发生率,这是通过产后24和48 h的隐蔽神经系统检查确定的,以及分娩后7-10和30天的电话随访确定的。次要结果包括分娩镇痛是否充分,产妇满意度和新生儿状况。结果:没有患者发生永久性神经系统改变。连续鞘内镇痛患者在产后24 h的早期镇痛效果更好,运动阻滞较少,瘙痒更多,产妇对疼痛的缓解满意度更高。鞘内导管明显更难以移除。两组在新生儿状态,硬膜穿刺后头痛,血流动力学稳定性或产科结局方面无显着差异。结论:通过28号导管为鞘内分娩镇痛提供舒芬太尼和布比卡因的神经系统并发症发生率不到1%,并能产生更好的初期疼痛缓解和更高的产妇满意度,但与之相比,其技术难度更大,导管失败硬膜外镇痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号